PROTACs targeting GSPT1, such as CC-90009, have been tested in clinical trials as monotherapy (NCT02848001) or in combination with azacitidine, venetoclax, or gilteritinib (NCT04336982) for relapsed and refractory (R/R) adult AML. The gene discussed is GSPT1; the disease is acute myeloid leukemia.